Since the first application in cancer therapy, monoclonal antibody (MAb) is shown of promising therapeutic effect. In spite of classical mechanism of actions exerted by MAb, such as neutralization, blocking, CDC, ADCC, therapeutic antibody could also act as agonists of the receptors, essentially replacing the activity of the normal ligand. The agonist activity can occur when the antibody binds the receptor in a manner that mimics the binding of the physiological ligand resulting in antibody-mediated agonism. To date, much of the agonistic antibody in clinical and pre-clinical studies target TNF family members, such as OX40, CD27, 4-1BB and DR5.https://www.creativebiolabs.net/agonistic-antibody_72.htm